{"component": "clause", "props": {"groups": [{"size": 59, "samples": [{"hash": "an788jVAlgb", "uri": "/contracts/an788jVAlgb#tail", "label": "Exclusive Agency Agreement (Innovative Payment Solutions, Inc.)", "score": 30.2032852173, "published": true}, {"hash": "kowPHBFXGmT", "uri": "/contracts/kowPHBFXGmT#tail", "label": "Exclusive Agency Agreement (Aikido Pharma Inc.)", "score": 29.6502399445, "published": true}, {"hash": "9vQfDA9TmaP", "uri": "/contracts/9vQfDA9TmaP#tail", "label": "Exclusive Agency Agreement (Immuron LTD)", "score": 29.5571517944, "published": true}], "snippet": "\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 shall be entitled to compensation under clauses (1) and (2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (\u201cTail Financing\u201d) to the extent that such financing or capital is provided to the Company by investors whom \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 had contacted during the Term or introduced to the Company during the Term, if such Tail Financing is consummated at any time within the 12-month period following the expiration or termination of this Agreement.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [126, 141]}, {"key": "private-offering", "type": "definition", "offset": [156, 172]}, {"key": "other-financing", "type": "clause", "offset": [176, 191]}, {"key": "tail-financing", "type": "clause", "offset": [237, 251]}, {"key": "to-the-extent", "type": "clause", "offset": [254, 267]}, {"key": "to-the-company", "type": "clause", "offset": [311, 325]}, {"key": "by-investors", "type": "clause", "offset": [326, 338]}, {"key": "during-the-term", "type": "clause", "offset": [369, 384]}, {"key": "at-any-time", "type": "clause", "offset": [469, 480]}, {"key": "following-the", "type": "definition", "offset": [508, 521]}, {"key": "expiration-or-termination-of-this-agreement", "type": "clause", "offset": [522, 565]}], "hash": "81fc92d748fa67f58b95a90d600eac11", "id": 1}, {"size": 8, "samples": [{"hash": "eDMcpPQoq2L", "uri": "/contracts/eDMcpPQoq2L#tail", "label": "Exclusive Agency Agreement (Bio-Path Holdings Inc)", "score": 26.8891162872, "published": true}, {"hash": "h76K8YRzeAH", "uri": "/contracts/h76K8YRzeAH#tail", "label": "Exclusive Agency Agreement (Bio-Path Holdings Inc)", "score": 26.1937026978, "published": true}], "snippet": "In the event, and only in the event, an Offering is not completed during the Term, W\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 shall be entitled to compensation under clauses (1) and (2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (\u201cTail Financing\u201d) to the extent that such financing or capital is provided to the Company by investors whom W\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 had contacted during the Term or introduced to the Company during the Term, if such Tail Financing is consummated at any time within the 12-month period following the expiration or termination of this Agreement.", "snippet_links": [{"key": "in-the-event", "type": "clause", "offset": [0, 12]}, {"key": "not-completed", "type": "clause", "offset": [52, 65]}, {"key": "during-the-term", "type": "clause", "offset": [66, 81]}, {"key": "with-respect-to", "type": "clause", "offset": [209, 224]}, {"key": "private-offering", "type": "definition", "offset": [239, 255]}, {"key": "other-financing", "type": "clause", "offset": [259, 274]}, {"key": "tail-financing", "type": "clause", "offset": [320, 334]}, {"key": "to-the-extent", "type": "clause", "offset": [337, 350]}, {"key": "to-the-company", "type": "clause", "offset": [394, 408]}, {"key": "by-investors", "type": "clause", "offset": [409, 421]}, {"key": "at-any-time", "type": "clause", "offset": [552, 563]}, {"key": "following-the", "type": "definition", "offset": [591, 604]}, {"key": "expiration-or-termination-of-this-agreement", "type": "clause", "offset": [605, 648]}], "hash": "77d46cf262c591b49575d5abc506656f", "id": 5}, {"size": 9, "samples": [{"hash": "g1W8pbCuR1F", "uri": "/contracts/g1W8pbCuR1F#tail", "label": "Placement Agent Agreement (First Choice Healthcare Solutions, Inc.)", "score": 35.2819976807, "published": true}, {"hash": "au0JdFF4QS", "uri": "/contracts/au0JdFF4QS#tail", "label": "Placement Agent Agreement (First Choice Healthcare Solutions, Inc.)", "score": 34.9342918396, "published": true}, {"hash": "gAjmltKM42v", "uri": "/contracts/gAjmltKM42v#tail", "label": "Placement Agent Agreement (SMX (Security Matters) Public LTD Co)", "score": 34.5920600891, "published": true}], "snippet": "If there is a Closing of the Offering, or if the Term ends prior to Closing of the Offering (other than a termination for cause in compliance with FINRA Rule 5110(g)(5)(B)(i)), Placement Agent shall be entitled to compensation under clauses 1(i) and 1(ii) hereunder, calculated in the manner set forth therein, with respect to any public offering or other equity financing of any kind (\u201cTail Financing\u201d) to the extent that such financing or capital is provided to the Company by investors that Placement Agent had introduced to the Company during the Term (if such Financing is consummated at any time within the 12-month period following the expiration or termination of this Agreement).", "snippet_links": [{"key": "closing-of-the-offering", "type": "clause", "offset": [14, 37]}, {"key": "term-ends", "type": "clause", "offset": [49, 58]}, {"key": "prior-to-closing", "type": "clause", "offset": [59, 75]}, {"key": "a-termination-for-cause", "type": "clause", "offset": [104, 127]}, {"key": "compliance-with-finra", "type": "clause", "offset": [131, 152]}, {"key": "agent-shall", "type": "definition", "offset": [187, 198]}, {"key": "with-respect-to", "type": "clause", "offset": [311, 326]}, {"key": "public-offering", "type": "definition", "offset": [331, 346]}, {"key": "equity-financing", "type": "clause", "offset": [356, 372]}, {"key": "tail-financing", "type": "clause", "offset": [387, 401]}, {"key": "to-the-extent", "type": "clause", "offset": [404, 417]}, {"key": "to-the-company", "type": "clause", "offset": [461, 475]}, {"key": "by-investors", "type": "clause", "offset": [476, 488]}, {"key": "during-the-term", "type": "clause", "offset": [540, 555]}, {"key": "at-any-time", "type": "clause", "offset": [590, 601]}, {"key": "following-the", "type": "definition", "offset": [629, 642]}, {"key": "expiration-or-termination-of-this-agreement", "type": "clause", "offset": [643, 686]}], "hash": "ae74ed7f503d2eca571c2ce170f8aca0", "id": 3}, {"size": 11, "samples": [{"hash": "5AiyfvmlR07", "uri": "/contracts/5AiyfvmlR07#tail", "label": "Ceo Incentive Stock Option Grant Agreement (Mast Therapeutics, Inc.)", "score": 26.4537982941, "published": true}, {"hash": "7UXUnDjn8hx", "uri": "/contracts/7UXUnDjn8hx#tail", "label": "Senior Executive Incentive Stock Option Grant Agreement (Mast Therapeutics, Inc.)", "score": 25.4654350281, "published": true}, {"hash": "fn51mUvQxXN", "uri": "/contracts/fn51mUvQxXN#tail", "label": "Senior Executive Incentive Stock Option Grant Agreement (Mast Therapeutics, Inc.)", "score": 24.4688568115, "published": true}], "snippet": "Subject to paragraph (a) of this Section 7, in the event of a Change in Control, to the extent the successor company (or a subsidiary or parent thereof) assumes or substitutes for the Option on substantially the same terms and conditions (which may include providing for settlement in the common stock of the successor company (or a subsidiary or parent thereof)), and in the event of an Involuntary Termination of the Grantee within 12 months following the date of the Change in Control, the Option shall become fully vested and exercisable, and may be exercised by the Grantee at any time until the close of business on the last calendar day of the 24th full calendar month following the date of such Involuntary Termination.", "snippet_links": [{"key": "subject-to", "type": "definition", "offset": [0, 10]}, {"key": "this-section-7", "type": "clause", "offset": [28, 42]}, {"key": "a-change-in-control", "type": "clause", "offset": [60, 79]}, {"key": "to-the-extent", "type": "clause", "offset": [81, 94]}, {"key": "successor-company", "type": "definition", "offset": [99, 116]}, {"key": "the-option", "type": "clause", "offset": [180, 190]}, {"key": "same-terms-and-conditions", "type": "definition", "offset": [212, 237]}, {"key": "for-settlement", "type": "clause", "offset": [267, 281]}, {"key": "the-common-stock", "type": "clause", "offset": [285, 301]}, {"key": "the-grantee", "type": "definition", "offset": [415, 426]}, {"key": "following-the", "type": "definition", "offset": [444, 457]}, {"key": "date-of", "type": "clause", "offset": [458, 465]}, {"key": "vested-and-exercisable", "type": "clause", "offset": [519, 541]}, {"key": "at-any-time", "type": "clause", "offset": [579, 590]}, {"key": "close-of-business", "type": "definition", "offset": [601, 618]}, {"key": "day-of", "type": "clause", "offset": [640, 646]}, {"key": "full-calendar-month", "type": "definition", "offset": [656, 675]}], "hash": "64a6a7ad712c01523518459966b8d2ef", "id": 2}, {"size": 9, "samples": [{"hash": "h57KRzm6w0X", "uri": "/contracts/h57KRzm6w0X#tail", "label": "Exclusive Agency Agreement (Kitov Pharma Ltd.)", "score": 27.3490753174, "published": true}, {"hash": "kZQfulwSfxY", "uri": "/contracts/kZQfulwSfxY#tail", "label": "Exclusive Agency Agreement (Kitov Pharma Ltd.)", "score": 27.2997951508, "published": true}], "snippet": "\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 shall be entitled to compensation under clauses (A)(1) and (A)(2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (\u201cTail Financing\u201d) to the extent that such Tail Financing is provided to the Company by investors whom \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 had contacted and brought over-the-wall during the Term as set forth in Exhibit B attached hereto (as may be updated from time to time by the Company and \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587), or introduced to the Company during Term; provided, however, that such Tail Financing is consummated during the period beginning on the date hereof and ending three months following the expiration of the Right of First Refusal period in Section (A)(4) above.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [132, 147]}, {"key": "private-offering", "type": "definition", "offset": [162, 178]}, {"key": "other-financing", "type": "clause", "offset": [182, 197]}, {"key": "tail-financing", "type": "clause", "offset": [243, 257]}, {"key": "to-the-extent", "type": "clause", "offset": [260, 273]}, {"key": "to-the-company", "type": "clause", "offset": [311, 325]}, {"key": "by-investors", "type": "clause", "offset": [326, 338]}, {"key": "during-the-term", "type": "clause", "offset": [395, 410]}, {"key": "exhibit-b", "type": "definition", "offset": [427, 436]}, {"key": "from-time-to-time", "type": "clause", "offset": [472, 489]}, {"key": "company-and-\u2587", "type": "clause", "offset": [497, 510]}, {"key": "during-term", "type": "clause", "offset": [551, 562]}, {"key": "beginning-on-the", "type": "clause", "offset": [641, 657]}, {"key": "date-hereof", "type": "clause", "offset": [658, 669]}, {"key": "following-the", "type": "definition", "offset": [694, 707]}, {"key": "right-of-first-refusal-period", "type": "definition", "offset": [726, 755]}], "hash": "c2db77e00a804b829af2afc3e5dbf641", "id": 4}, {"size": 6, "samples": [{"hash": "8w0xryvM1Nj", "uri": "/contracts/8w0xryvM1Nj#tail", "label": "Engagement Agreement (Caltier Fund I LP)", "score": 34.1225204468, "published": true}, {"hash": "1DQsDpVGWmK", "uri": "/contracts/1DQsDpVGWmK#tail", "label": "Cpgo Plus Agreement (Caltier Fund I LP)", "score": 31.8281993866, "published": true}, {"hash": "2eYeUxtEwnv", "uri": "/contracts/2eYeUxtEwnv#tail", "label": "Cpgo Plus Agreement (Caltier Fund I LP)", "score": 31.6475009918, "published": true}], "snippet": "Company shall pay to Castle pursuant to the success fee set forth in the fee schedule contained herein with respect to any Transaction with an Investor which is consummated, or for which a definitive agreement has been signed, within 3 months after the later of the closing of the Transaction or any termination of the Agreement.", "snippet_links": [{"key": "pay-to", "type": "definition", "offset": [14, 20]}, {"key": "pursuant-to-the", "type": "definition", "offset": [28, 43]}, {"key": "success-fee", "type": "definition", "offset": [44, 55]}, {"key": "fee-schedule", "type": "definition", "offset": [73, 85]}, {"key": "with-respect-to", "type": "clause", "offset": [103, 118]}, {"key": "an-investor", "type": "definition", "offset": [140, 151]}, {"key": "definitive-agreement", "type": "clause", "offset": [189, 209]}, {"key": "the-closing-of-the-transaction", "type": "clause", "offset": [262, 292]}, {"key": "termination-of-the-agreement", "type": "clause", "offset": [300, 328]}], "hash": "ddd8e6b09f45aa24ee1e97d47af41d48", "id": 7}, {"size": 5, "samples": [{"hash": "6XlseHfWg5H", "uri": "/contracts/6XlseHfWg5H#tail", "label": "Exclusive Agency Agreement (Arcadia Biosciences, Inc.)", "score": 29.6214923859, "published": true}, {"hash": "2r48AbyVMZ8", "uri": "/contracts/2r48AbyVMZ8#tail", "label": "Exclusive Agency Agreement (Arcadia Biosciences, Inc.)", "score": 27.9733066559, "published": true}], "snippet": "W\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 shall be entitled to compensation under clauses (1) and (2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of equity or convertible debt securities that is not described on Exhibit A (\u201cTail Financing\u201d) to the extent that such financing or capital is provided to the Company by investors whom W\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 introduced to the Company during the Term in connection with a public Offering or investors who have been brought over-the-wall by W\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 in connection with a registered direct offering or private placement, if such Tail Financing is consummated at any time within the 12-month period following the end of the Term.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [126, 141]}, {"key": "private-offering", "type": "definition", "offset": [156, 172]}, {"key": "other-financing", "type": "clause", "offset": [176, 191]}, {"key": "convertible-debt-securities", "type": "clause", "offset": [236, 263]}, {"key": "exhibit-a", "type": "definition", "offset": [289, 298]}, {"key": "tail-financing", "type": "clause", "offset": [301, 315]}, {"key": "to-the-extent", "type": "clause", "offset": [318, 331]}, {"key": "to-the-company", "type": "clause", "offset": [375, 389]}, {"key": "by-investors", "type": "clause", "offset": [390, 402]}, {"key": "during-the-term", "type": "clause", "offset": [445, 460]}, {"key": "in-connection-with", "type": "clause", "offset": [461, 479]}, {"key": "public-offering", "type": "definition", "offset": [482, 497]}, {"key": "registered-direct-offering", "type": "definition", "offset": [582, 608]}, {"key": "private-placement", "type": "clause", "offset": [612, 629]}, {"key": "at-any-time", "type": "clause", "offset": [669, 680]}, {"key": "following-the", "type": "definition", "offset": [708, 721]}, {"key": "end-of-the-term", "type": "clause", "offset": [722, 737]}], "hash": "aa45326560c4fa8450dd366fd829f271", "id": 8}, {"size": 4, "samples": [{"hash": "f6Yx0bji2mQ", "uri": "/contracts/f6Yx0bji2mQ#tail", "label": "Cmo Incentive Stock Option Grant Agreement (Mast Therapeutics, Inc.)", "score": 26.4537982941, "published": true}, {"hash": "h7KjaljWcnm", "uri": "/contracts/h7KjaljWcnm#tail", "label": "Cmo Incentive Stock Option Grant Agreement (Mast Therapeutics, Inc.)", "score": 25.4654350281, "published": true}, {"hash": "9I0W9WhZI2Z", "uri": "/contracts/9I0W9WhZI2Z#tail", "label": "Incentive Stock Option Grant Agreement (Mast Therapeutics, Inc.)", "score": 24.4688568115, "published": true}], "snippet": "In the event of a Change in Control, to the extent the successor company (or a subsidiary or parent thereof) assumes or substitutes for the Option on substantially the same terms and conditions (which may include providing for settlement in the common stock of the successor company (or a subsidiary or parent thereof)) and in the event of an Involuntary Termination of the Grantee within 24 months following the date of the Change in Control, the Option shall become fully vested and exercisable, and may be exercised by the Grantee at any time until the close of business on the last calendar day of the 18th full calendar month following the date of such Involuntary Termination or by the end of the term of the Option pursuant to Section 3, whichever is earlier.", "snippet_links": [{"key": "a-change-in-control", "type": "clause", "offset": [16, 35]}, {"key": "to-the-extent", "type": "clause", "offset": [37, 50]}, {"key": "successor-company", "type": "definition", "offset": [55, 72]}, {"key": "same-terms-and-conditions", "type": "definition", "offset": [168, 193]}, {"key": "for-settlement", "type": "clause", "offset": [223, 237]}, {"key": "the-common-stock", "type": "clause", "offset": [241, 257]}, {"key": "the-grantee", "type": "definition", "offset": [370, 381]}, {"key": "following-the", "type": "definition", "offset": [399, 412]}, {"key": "date-of", "type": "clause", "offset": [413, 420]}, {"key": "vested-and-exercisable", "type": "clause", "offset": [474, 496]}, {"key": "at-any-time", "type": "clause", "offset": [534, 545]}, {"key": "close-of-business", "type": "definition", "offset": [556, 573]}, {"key": "day-of", "type": "clause", "offset": [595, 601]}, {"key": "full-calendar-month", "type": "definition", "offset": [611, 630]}, {"key": "term-of-the-option", "type": "clause", "offset": [703, 721]}, {"key": "pursuant-to-section-3", "type": "clause", "offset": [722, 743]}], "hash": "e6d9984f08074bd10f166e7efa173a38", "id": 10}, {"size": 4, "samples": [{"hash": "2EiHuHxtGUG", "uri": "/contracts/2EiHuHxtGUG#tail", "label": "Exclusive Agency Agreement (Arch Therapeutics, Inc.)", "score": 28.1156749725, "published": true}, {"hash": "9mgJvCPDVVI", "uri": "/contracts/9mgJvCPDVVI#tail", "label": "Exclusive Agency Agreement (Emerald Bioscience, Inc.)", "score": 27.5708427429, "published": true}, {"hash": "kib1mmXoBCb", "uri": "/contracts/kib1mmXoBCb#tail", "label": "Exclusive Agency Agreement (Emerald Bioscience, Inc.)", "score": 27.1108837128, "published": true}], "snippet": "\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 shall be entitled to compensation under clauses (1) and (2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (\u201cTail Financing\u201d) to the extent that such financing or capital is provided to the Company by investors whom \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 had contacted during the Term or introduced to the Company during the Term, if such Tail Financing is consummated at any time within the 12-month period following the expiration or termination of this Agreement; provided, however, that any of the investors who are listed on Exhibit B hereto shall be excluded from this Paragraph A.4.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [126, 141]}, {"key": "private-offering", "type": "definition", "offset": [156, 172]}, {"key": "other-financing", "type": "clause", "offset": [176, 191]}, {"key": "tail-financing", "type": "clause", "offset": [237, 251]}, {"key": "to-the-extent", "type": "clause", "offset": [254, 267]}, {"key": "to-the-company", "type": "clause", "offset": [311, 325]}, {"key": "by-investors", "type": "clause", "offset": [326, 338]}, {"key": "during-the-term", "type": "clause", "offset": [369, 384]}, {"key": "at-any-time", "type": "clause", "offset": [469, 480]}, {"key": "following-the", "type": "definition", "offset": [508, 521]}, {"key": "expiration-or-termination-of-this-agreement", "type": "clause", "offset": [522, 565]}, {"key": "of-the-investors", "type": "clause", "offset": [595, 611]}, {"key": "exhibit-b", "type": "definition", "offset": [630, 639]}], "hash": "4fe718fa99c5c195e46c64540dd5e850", "id": 9}, {"size": 7, "samples": [{"hash": "hDuMJXUz7G8", "uri": "/contracts/hDuMJXUz7G8#tail", "label": "Underwriting Agreement (Evvolutions LeadTech Inc)", "score": 37.1697463989, "published": true}, {"hash": "645tpLbGuiq", "uri": "/contracts/645tpLbGuiq#tail", "label": "Underwriting Agreement (Micropolis Holding Co)", "score": 36.1895942688, "published": true}, {"hash": "6n3jQy3RgAj", "uri": "/contracts/6n3jQy3RgAj#tail", "label": "Underwriting Agreement (Micropolis Holding Co)", "score": 36.1019859314, "published": true}], "snippet": "The Company agrees that if at any time prior to the first anniversary of the final Closing Date, the Company, or any of its affiliates, shall enter into any transaction (including, without limitation, any merger, consolidation, acquisition, financing, joint venture or other arrangement) with any party directly introduced to the Company by the Representative during the Offering and the aforementioned time period, the Company shall pay the Representative a success fee, at the closing thereof, equal to 1% of the consideration or value receive by the Company and/or its shareholders.", "snippet_links": [{"key": "the-company-agrees", "type": "clause", "offset": [0, 18]}, {"key": "at-any-time", "type": "clause", "offset": [27, 38]}, {"key": "prior-to-the", "type": "clause", "offset": [39, 51]}, {"key": "first-anniversary", "type": "clause", "offset": [52, 69]}, {"key": "final-closing-date", "type": "clause", "offset": [77, 95]}, {"key": "without-limitation", "type": "clause", "offset": [181, 199]}, {"key": "joint-venture", "type": "definition", "offset": [252, 265]}, {"key": "other-arrangement", "type": "definition", "offset": [269, 286]}, {"key": "to-the-company", "type": "clause", "offset": [323, 337]}, {"key": "the-representative", "type": "clause", "offset": [341, 359]}, {"key": "the-offering", "type": "definition", "offset": [367, 379]}, {"key": "time-period", "type": "definition", "offset": [403, 414]}, {"key": "the-company-shall", "type": "clause", "offset": [416, 433]}, {"key": "success-fee", "type": "definition", "offset": [459, 470]}, {"key": "at-the-closing", "type": "definition", "offset": [472, 486]}, {"key": "equal-to", "type": "definition", "offset": [496, 504]}, {"key": "the-consideration", "type": "clause", "offset": [511, 528]}, {"key": "by-the-company", "type": "clause", "offset": [546, 560]}], "hash": "73f551a90ca84c7992b979c0839f3808", "id": 6}], "next_curs": "Ck0SR2oVc35sYXdpbnNpZGVyY29udHJhY3RzcikLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ig10YWlsIzAwMDAwMDBhDKIBAmVuGAAgAA==", "clause": {"title": "Tail", "size": 252, "parents": [["compensation-reimbursement", "Compensation; Reimbursement"], ["change-in-control", "Change in Control"], ["right-of-first-negotiation-tail", "Right of First Negotiation Tail"], ["covenants-and-agreements-of-the-company", "Covenants and Agreements of the Company"], ["compensation", "Compensation"]], "children": [["tail", "Tail"], ["procedure", "Procedure"], ["", ""], ["holders-right-to-receive-notice", "Holder\u2019s Right to Receive Notice"], ["transfer", "Transfer"]], "id": "tail", "related": [["tail-coverage", "Tail Coverage", "<strong>Tail</strong> Coverage"], ["coverage", "Coverage", "Coverage"], ["insurance", "Insurance", "Insurance"], ["trauma-insurance", "Trauma Insurance", "Trauma Insurance"], ["fire-insurance", "Fire Insurance", "Fire Insurance"]], "related_snippets": [], "updated": "2026-05-03T04:25:58+00:00"}, "json": true, "cursor": ""}}